Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3- d]pyrimidine tyrosine kinase inhibitors

Biochemical Pharmacology

Volumn 60, Issue 7, 2000, Pages 885-898

  Kraker, Alan J ^a   Hartl, Brian G ^a   Amar, Aneesa M ^a   Barvian, Mark R ^a   Showalter, H D Hollis ^a   Moore, Charles W ^a  

^a PFIZER INC   (United States)

Author keywords

Antitumor; bFGFr; c Src kinase; EGFr; PDGFr; Phosphorylation; Pyridopyrimidine; Tyrosine kinase inhibition

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; PAXILLIN; PD 0158780; PD 0166285; PD 0166326; PD 0173952; PD 0173955; PD 0173956; PD 0173958; PD 0179483; PD 0180970; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P130; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE; COLON CANCER; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; ONCOGENE SRC; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL;

CELL CYCLE; CELL DIVISION; DNA; ENZYME INHIBITORS; HT29 CELLS; HUMANS; PHENOTYPE; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 0034308176     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00405-6     Document Type: Article

References (68)

1. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 13:1997;513-609.
2. Biscardi J.S., Tice D.A., Parsons S.J. c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res. 76:1999;61-119.
3. Egan C., Pang A., Durda D., Cheng H.-C., Wang J.H., Fujita D.J. Activation of Src in human breast tumor cell lines Elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530 . Oncogene. 18:1999;1227-1237.
4. Verbeek B.S., Vroom T.M., Adriaansen-Slot S.S., Ottenhoff-Kalff A.E., Geertzema J.G.N., Hennipman A., Rijksen G. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol. 180:1996;383-388.
5. c-src in progressive stages of human colorectal cancer. J Clin Invest. 91:1993;53-60.
6. Staley C.A., Parikh N.U., Gallick G.E. Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Differ. 8:1997;269-274.
7. Iravani S., Mao W., Fu L., Karl R., Yeatman T., Jove R., Coppola D. Elevated c-Src protein expression is an early event in colonic neoplasia. Lab Invest. 78:1998;365-371.
8. Mao W., Irby R., Coppola D., Fu L., Wloch M., Turner J., Yu H., Garcia R., Jove R., Yeatman T.J. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene. 15:1997;3083-3090.
9. Irby R.B., Mao W., Coppola D., Kang J., Loubeau J.M., Trudeau W., Karl R., Fujita D.J., Jove R., Yeatman T.J. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet. 21:1999;187-190.
10. van Oijen M.G.C.T., Rijksen G., ten Broek F.W., Slootweg P.J. Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders. J Oral Pathol Med. 27:1998;147-152.
11. Lutz M.P., Silke Eßer I.B., Flossmann-Kast B.B.M., Vogelmann R., Lührs H., Friess H., Büchler M.W., Adler G. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun. 243:1998;503-508.
12. Roche S., Koegl M., Barone M.V., Roussel M.F., Courtneidge S.A. DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases. Mol Cell Biol. 15:1995;1102-1109.
13. Stover D.R., Becker M., Liebetanz J., Lydon N.B. Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85α J Biol Chem. 270:1995;15591-15597.
14. Sato K., Sato A., Aoto M., Fukami Y. Site-specific association of c-Src with epidermal growth factor receptor in A431 cells. Biochem Biophys Res Commun. 210:1995;844-851.
15. Brunton V.G., Ozanne B.W., Paraskeva C., Frame M.C. A role for epidermal growth factor receptor, c-Src, and focal adhesion kinase in an in vitro model for the progression of colon cancer. Oncogene. 14:1997;283-293.
16. c-src is necessary for human vascular smooth muscle cell migration. Surgery. 122:1997;138-145.
17. Declan Fleming R.Y., Ellis L.M., Parikh N.U., Liu W., Staley C.A., Gallick G.E. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase. Surgery. 122:1997;501-507.
18. Sheffield L.G. C-Src activation by ErbB2 leads to attachment-independent growth of human breast epithelial cells. Biochem Biophys Res Commun. 250:1998;27-31.
19. Gelderloos J.A., Rosenkranz S., Bazenet C., Kazlauskas A. A role for Src in signal relay by the platelet-derived growth factor α receptor. J Biol Chem. 273:1998;5908-5915.
20. L expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene. 18:1999;4654-4662.
21. Wilde A., Beattie E.C., Lem L., Riethof D.A., Liu S.-H., Mobley W.C., Soriano P., Brodsky F.M. EGF receptor signaling stimulates SRC kinase phosphorylation of clathrin, influencing clathrin redistribution and EGF uptake. Cell. 96:1999;677-687.
22. Tice D.A., Biscardi J.S., Nickles A.L., Parsons S.J. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA. 96:1999;1415-1420.
23. 1101 is associated with modulation of receptor function. J Biol Chem. 274:1999;8335-8343.
24. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., Connelly P.A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem. 271:1996;695-701.
25. Bishop A.C., Kung C-y, Shah K., Witucki L., Shokat K.M., Liu Y. Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach. J Am Chem Soc. 121:1999;627-631.
26. Missbach M., Jeschke M., Feyen J., Müller K., Glatt M., Green J., Susa M. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 24:1999;437-449.
27. src by analogs of 5,10-dihydropyrimido[4,5-b]quinolin-4(1H)-one. Bioorg Med Chem Lett. 5:1995;1007-1010.
28. c-src. Bioorg Med Chem Lett. 5:1995;2423-2428.
29. lck tyrosine kinase by isothiazolones. Arch Biochem Biophys. 364:1999;19-29.
30. c-src protein tyrosine kinase Conformational and topographical constraints in peptide design . J Med Chem. 41:1998;2252-2260.
31. Zheng Z-b, Nagai S., Iwanami N., Kobayashi A., Hijikata M., Natori S., Sankawa U. Selective inhibition of src protein tyrosine kinase by analogues of 5-S-glutathionyl-β-alanyl-L-dopa. Chem Pharm Bull (Tokyo). 46:1998;1950-1951.
32. Profit A.A., Lee T.R., Lawrence D.S. Bivalent inhibitors of protein tyrosine kinases. J Am Chem Soc. 121:1999;280-283.
33. Ramdas L., Bunnin B.A., Plunkett M.J., Sun G., Ellman J., Gallick G., Budde R.J.A. Benzodiazepine compounds as inhibitors of the Src protein tyrosine kinase Screening of a combinatorial library of 1,4-benzodiazepines . Arch Biochem Biophys. 368:1999;394-400.
34. Boschelli D.H., Wu Z., Klutchko S.R., Showalter H.D.H., Hamby J.M., Lu G.H., Major T.C., Dahring T.K., Batley B., Panek R.L., Keiser J., Hartl B.G., Kraker A.J., Klohs W.D., Roberts B.J., Patmore S., Elliott W.L., Steinkampf R., Bradford L.A., Hallak H., Doherty A.M. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidine Identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors . J Med Chem. 41:1998;4365-4377.
35. Klutchko S.R., Hamby J.M., Boschelli D.H., Wu Z., Kraker A.J., Amar A.M., Hartl B.G., Shen C., Klohs W.D., Steinkampf R.W., Driscoll D.L., Nelson J.M., Elliott W.L., Roberts B.J., Stoner C.L., Vincent P.W., Dykes D.J., Panek R.L., Lu G.H., Major T.C., Dahring T.K., Hallak H., Bradford L.A., Showalter H.D.H., Doherty A.M. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity . J Med Chem. 41:1998;3276-3292.
36. Dahring T.K., Lu G.H., Hamby J.M., Batley B.L., Kraker A.J., Panek R.L. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD089828, a new synthetic protein tyrosine kinase inhibitor. J Pharmacol Exp Ther. 281:1997;1446-1456.
37. Fry D.W., Kraker A.J., Connors R.C., Elliott W.L., Nelson J.M., Showalter H.D.H., Leopold W.R. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anticancer Drug Des. 9:1994;331-351.
38. Nelson J.M., Fry D.W. Cytoskeletal and morphological changes associated with the specific suppression of the epidermal growth factor tyrosine kinase activity in A431 human epidermoid carcinoma. Exp Cell Res. 233:1997;383-390.
39. Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., Connors R.W., Bridges A.J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 265:1994;1093-1095.
40. Cleland W.W. Statistical analysis of enzyme kinetic data. Methods Enzymol. 63:1979;103-112.
41. Zhong Z., Wen Z., Darnell J.E. Stat3, A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 264:1994;95-98.
42. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1994;1415-1421.
43. Yu C.-L., Meyer D.J., Campbell G.S., Larner A.C., Carter-Su C., Schwartz J., Jove R. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 269:1995;81-83.
44. Darnell J.E. STATs and gene regulation. Science. 277:1997;1630-1635.
45. Cirri P., Chiarugi P., Marra F., Raugei G., Camici G., Manao G., Ramponi G. c-Src activates both STAT1 and STAT3 in PDGF-stimulated NIH3T3 cells. Biochem Biophys Res Commun. 239:1997;493-497.
46. Garcia R., Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci. 5:1998;79-85.
47. Olayioye M.A., Beuvink I., Horsch K., Daly J.M., Hynes N.E. ErbB receptor-induced activation of Stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem. 274:1999;17209-17218.
48. Richardson A., Malik R.K., Hildebrand J.D., Parsons J.T. Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK A role for paxillin tyrosine phosphorylation . Mol Cell Biol. 17:1997;6906-6914.
49. Ishida T., Ishida M., Suero J., Takahashi M., Berk B.C. Agonist-stimulated cytoskeletal reorganization and signal transduction at focal adhesions in vascular smooth muscle cells require c-Src. J Clin Invest. 103:1999;789-797.
50. Thomas J.W., Ellis B., Boerner R.J., Knight W.B., White G.C. II, Schaller M.D. SH2- and SH3-mediated interactions between focal adhesion kinase and Src. J Biol Chem. 273:1998;577-583.
51. cas, and Nck adaptor proteins . Mol Cell Biol. 17:1997;1702-1713.
52. cas signaling complex formation upon integrin-mediated cell adhesion A role for Src family kinases . Mol Cell Biol. 16:1996;2606-2613.
53. Cas, a substrate associated with v-Src and v-Crk, localizes to focal adhesions and binds to focal adhesion kinase. J Biol Chem. 271:1996;13649-13655.
54. Cas) are elevated in cytoskeleton-associated fractions following adhesion and Src transformation. Requirements for Src kinase activity and FAK proline-rich motifs. J Biol Chem. 272:1997;5501-5509.
55. Fry D.W., Nelson J.M., Slintak V., Keller P.R., Rewcastle G.W., Denny W.A., Zhou H., Bridges A.J. Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem Pharmacol. 54:1997;877-887.
56. Graves R., Davies R., Brophy G., O'Beirne G., Cook N. Noninvasive real-time method for the examination of thymidine uptake events - Application of the method to V-79 cell synchrony studies. Anal Biochem. 248:1997;251-257.
57. Graves R., Davies R., Owen P., Clynes M., Cleary I., O'Beirne G. An homogeneous assay for measuring the uptake and efflux of radiolabelled drugs in adherent cells. J Biochem Biophys Methods. 34:1997;177-187.
58. 2 for fibroblast cell division. Science. 269:1995;1567-1569.
59. Klohs W.D., Fry D.W., Kraker A.J. Inhibitors of tyrosine kinase. Curr Opin Oncol. 9:1997;562-568.
60. Showalter H.D.H., Kraker A.J. Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases. Pharmacol Ther. 76:1997;55-71.
61. Wakeling A.E., Barker A.J., Davies D.H., Brown D.S., Green L.R., Cartlidge S.A., Woodburn J.R. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat. 38:1996;67-73.
62. Traxler P.M., Furet P., Mett H., Buchdunger E., Meyer T., Lydon N. 4-(Phenylamino)pyrrolopyrimidines Potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase . J Med Chem. 39:1996;2285-2292.
63. Turkson J., Bowman T., Garcia R., Caldenhoven E., De Groot R.P., Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 18:1998;2545-2552.
64. src is critical for stretch-induced orienting response in fibroblasts. J Cell Sci. 112:1999;1365-1373.
65. Twamley-Stein G.M., Pepperkok R., Ansorge W., Courtneidge S.A. The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells. Proc Natl Acad Sci USA. 90:1993;7696-7700.
66. Klinghoffer R.A., Sachsenmaier C., Cooper J.A., Soriano P. Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J. 18:1999;2459-2471.
67. DeMali K.A., Godwin S.L., Soltoff S.P., Kazlauskas A. Multiple roles for Src in a PDGF-stimulated cell. Exp Cell Res. 253:1999;271-279.
68. Moasser M.M., Srethapakdi M., Sachar K.S., Kraker A.J., Rosen N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 59:1999;6145-6152.